Role of NOD-like receptor protein 3 inflammasome in the development and progression of hepatocellular carcinoma

Xuehai YU; Bendong CHEN; Yimin LIU; Yongxin MA; Xusheng ZHANG; Hongcai ZHOU; Haiyan MA

doi:10.12449/JCH240229

Volume 40 Issue 2

Feb. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(2): 397-401

PDF( 942 KB)

Role of NOD-like receptor protein 3 inflammasome in the development and progression of hepatocellular carcinoma

DOI: 10.12449/JCH240229

1a.
Department of Pediatric Surgery，General Hospital of Ningxia Medical University，Yinchuan 750000，China
1b.
Department of Hepatobiliary Surgery，General Hospital of Ningxia Medical University，Yinchuan 750000，China
2.
Ningxia Medical University，Yinchuan 750000，China

Research funding:

Key Project of Ningxia Natural Science Foundation (2023AAC02073);

School Level Project of Ningxia Medical University (XM2023022)

More Information

Corresponding author: CHEN Bendong， chenbendong@nxmu.edu.cn （ORCID： 0009-0001-8566-9269）
Received Date: 2023-06-02
Accepted Date: 2023-08-01
Published Date: 2024-02-19

Abstract

Abstract

In recent years， NOD-like receptor protein 3 （NLRP3） inflammasome in tumors has become a research hotspot， especially in melanoma， colorectal cancer， lung cancer， and breast cancer， and more and more evidence has shown that inflammation plays a role in the development， progression， angiogenesis， and invasion of cancer. Hepatocellular carcinoma （HCC） is the most common type of primary liver cancer， and there are still controversies over the role of NLRP3 inflammasome in the development and progression of HCC. Therefore， this article reviews the potential impact of NLRP3 inflammasome in the progression of HCC and its mechanism of action in anticancer therapy， and it is believed that NLRP3 inflammasome can be used as an effective therapeutic target for HCC patients.
- Carcinoma， Hepatocellular,
- NLR Family， Pyrin Domain-Containing 3 Protein,
- Pyroptosis

FullText(HTML)

References(38)

References

[1]	LI Z, ZHU JY. Interpretation of standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 5): 1027- 1029. DOI: 10.3969/j.issn.1001-5256.2022.05.010. 李照, 朱继业.《原发性肝癌诊疗指南(2022年版)》解读[J]. 临床肝胆病杂志, 2022, 38( 5): 1027- 1029. DOI: 10.3969/j.issn.1001-5256.2022.05.010.
[2]	YANG JD, HAINAUT P, GORES GJ, et al. A global view of hepatocellular carcinoma: Trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 10): 589- 604. DOI: 10.1038/s41575-019-0186-y.
[3]	HUANG XY, CHAO X, HUANG F. Research progress on role of pyroptosis in progress of primary liver cancer[J]. Drug Eval Res, 2021, 44( 7): 1535- 1540. DOI: 10.7501/j.issn.1674-6376.2021.07.026. 黄鑫悦, 晁旭, 黄峰. 细胞焦亡在原发性肝癌进展中的作用研究进展[J]. 药物评价研究, 2021, 44( 7): 1535- 1540. DOI: 10.7501/j.issn.1674-6376.2021.07.026.
[4]	KARKI R, KANNEGANTI TD. Diverging inflammasome signals in tumorigenesis and potential targeting[J]. Nat Rev Cancer, 2019, 19( 4): 197- 214. DOI: 10.1038/s41568-019-0123-y.
[5]	KANTONO M, GUO BC. Inflammasomes and cancer: The dynamic role of the inflammasome in tumor development[J]. Front Immunol, 2017, 8: 1132. DOI: 10.3389/fimmu.2017.01132.
[6]	XIA XJ, WANG X, CHENG Z, et al. The role of pyroptosis in cancer: Pro-cancer or pro-“host”?[J]. Cell Death Dis, 2019, 10( 9): 650. DOI: 10.1038/s41419-019-1883-8.
[7]	DAGENAIS M, SKELDON A, SALEH M. The inflammasome: In memory of Dr. Jurg Tschopp[J]. Cell Death Differ, 2012, 19( 1): 5- 12. DOI: 10.1038/cdd.2011.159.
[8]	SCHRODER K, TSCHOPP J. The inflammasomes[J]. Cell, 2010, 140( 6): 821- 832. DOI: 10.1016/j.cell.2010.01.040.
[9]	MISSIROLI S, PERRONE M, BONCOMPAGNI C, et al. Targeting the NLRP3 inflammasome as a new therapeutic option for overcoming cancer[J]. Cancers, 2021, 13( 10): 2297. DOI: 10.3390/cancers13102297.
[10]	MALIK A, KANNEGANTI TD. Inflammasome activation and assembly at a glance[J]. J Cell Sci, 2017, 130( 23): 3955- 3963. DOI: 10.1242/jcs.207365.
[11]	PATEL MN, CARROLL RG, GALVÁN-PEÑA S, et al. Inflammasome priming in sterile inflammatory disease[J]. Trends Mol Med, 2017, 23( 2): 165- 180. DOI: 10.1016/j.molmed.2016.12.007.
[12]	MOOSSAVI M, PARSAMANESH N, BAHRAMI A, et al. Role of the NLRP3 inflammasome in cancer[J]. Mol Cancer, 2018, 17( 1): 158. DOI: 10.1186/s12943-018-0900-3.
[13]	TSAI YM, CHIANG KH, HUNG JY, et al. Der f1 induces pyroptosis in human bronchial epithelia via the NLRP3 inflammasome[J]. Int J Mol Med, 2018, 41( 2): 757- 764. DOI: 10.3892/ijmm.2017.3310.
[14]	TANG YL, TAO Y, ZHU L, et al. Role of NLRP3 inflammasome in hepatocellular carcinoma: A double-edged sword[J]. Int Immunopharmacol, 2023, 118: 110107. DOI: 10.1016/j.intimp.2023.110107.
[15]	SHI JJ, ZHAO Y, WANG K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death[J]. Nature, 2015, 526( 7575): 660- 665. DOI: 10.1038/nature15514.
[16]	HAMARSHEH S, ZEISER R. NLRP3 inflammasome activation in cancer: A double-edged sword[J]. Front Immunol, 2020, 11: 1444. DOI: 10.3389/fimmu.2020.01444.
[17]	MAMUN A AL, MIMI AA, AZIZ MA, et al. Role of pyroptosis in cancer and its therapeutic regulation[J]. Eur J Pharmacol, 2021, 910: 174444. DOI: 10.1016/j.ejphar.2021.174444.
[18]	INCHINGOLO R, POSA A, MARIAPPAN M, et al. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions[J]. World J Gastroenterol, 2019, 25( 32): 4614- 4628. DOI: 10.3748/wjg.v25.i32.4614.
[19]	CHEN WQ, ZHENG RS, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66( 2): 115- 132. DOI: 10.3322/caac.21338.
[20]	ZENG HM, CHEN WQ, ZHENG RS, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6( 5): e555- e567. DOI: 10.1016/S2214-109X(18)30127-X.
[21]	SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
[22]	VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400( 10360): 1345- 1362. DOI: 10.1016/S0140-6736(22)01200-4.
[23]	WEI Q, MU K, LI T, et al. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression[J]. Lab Invest, 2014, 94( 1): 52- 62. DOI: 10.1038/labinvest.2013.126.
[24]	LIU BY, ZHOU ZW, JIN Y, et al. Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma[J]. J Immunother Cancer, 2022, 10( 1): e003069. DOI: 10.1136/jitc-2021-003069.
[25]	THI HTH, HONG S. Inflammasome as a therapeutic target for cancer prevention and treatment[J]. J Cancer Prev, 2017, 22( 2): 62- 73. DOI: 10.15430/JCP.2017.22.2.62.
[26]	JIANG S, ZHANG Y, ZHENG JH, et al. Potentiation of hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation[J]. Pharmacol Res, 2017, 117: 82- 93. DOI: 10.1016/j.phrs.2016.11.040.
[27]	FAN SH, WANG YY, LU J, et al. Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome[J]. PLoS One, 2014, 9( 2): e89961. DOI: 10.1371/journal.pone.0089961.
[28]	DALEY D, MANI VR, MOHAN N, et al. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma[J]. J Exp Med, 2017, 214( 6): 1711- 1724. DOI: 10.1084/jem.20161707.
[29]	DING Y, YAN YL, DONG YH, et al. NLRP3 promotes immune escape by regulating immune checkpoints: A pan-cancer analysis[J]. Int Immunopharmacol, 2022, 104: 108512. DOI: 10.1016/j.intimp.2021.108512.
[30]	WAN LF, YUAN X, LIU MT, et al. miRNA-223-3p regulates NLRP3 to promote apoptosis and inhibit proliferation of hep3B cells[J]. Exp Ther Med, 2018, 15( 3): 2429- 2435. DOI: 10.3892/etm.2017.5667.
[31]	SONOHARA F, INOKAWA Y, KANDA M, et al. Association of inflammasome components in background liver with poor prognosis after curatively-resected hepatocellular carcinoma[J]. Anticancer Res, 2017, 37( 1): 293- 300. DOI: 10.21873/anticanres.11320.
[32]	WANG L, QIN XW, LIANG JM, et al. Induction of pyroptosis: A promising strategy for cancer treatment[J]. Front Oncol, 2021, 11: 635774. DOI: 10.3389/fonc.2021.635774.
[33]	CHEN YF, LI S, SHI Y, et al. Research progress on atherosclerosis induced by clonal hematopoiesis of indeterminate potential and the therapeutic effect of NLRP3 inflammasome[J]. China Med Herald, 2023, 20( 21): 40- 44. DOI: 10.20047/j.issn1673-7210.2023.21.08. 陈雅芳, 李思, 史洋, 等. 潜质未定克隆性造血致动脉粥样硬化及NLRP3炎性小体治疗作用研究进展[J]. 中国医药导报, 2023, 20( 21): 40- 44. DOI: 10.20047/j.issn1673-7210.2023.21.08.
[34]	CHU Q, JIANG YN, ZHANG W, et al. Pyroptosis is involved in the pathogenesis of human hepatocellular carcinoma[J]. Oncotarget, 2016, 7( 51): 84658- 84665. DOI: 10.18632/oncotarget.12384.
[35]	CHEN YF, QI HY, WU FL. Euxanthone exhibits anti-proliferative and anti-invasive activities in hepatocellular carcinoma by inducing pyroptosis: Preliminary results[J]. Eur Rev Med Pharmacol Sci, 2018, 22( 23): 8186- 8196. DOI: 10.26355/eurrev_201812_16511.
[36]	WEI Q, ZHU R, ZHU JY, et al. E2-induced activation of the NLRP3 inflammasome triggers pyroptosis and inhibits autophagy in HCC cells[J]. Oncol Res, 2019, 27( 7): 827- 834. DOI: 10.3727/096504018X15462920753012.
[37]	SHARIF H, WANG L, WANG WL, et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome[J]. Nature, 2019, 570( 7761): 338- 343. DOI: 10.1038/s41586-019-1295-z.
[38]	YAN ZL, DA QG, LI ZF, et al. Inhibition of NEK7 suppressed hepatocellular carcinoma progression by mediating cancer cell pyroptosis[J]. Front Oncol, 2022, 12: 812655. DOI: 10.3389/fonc.2022.812655.

Relative Articles

[1]	Xiaomeng YAO, Keke SUN, Yunkai LIN, Hui WANG, Liwei DONG, Lei CHEN, Heping HU. Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2524-2530. doi: 10.12449/JCH241225
[2]	Qian HUANG, Zhuoyuan WANG, Ziming AN, Xin XIN, Qinmei SUN, Xiaojun GOU, Yiyang HU, Qin FENG. Effect of NOD‑like receptor family pyrin domain containing 3 knockdown on a mouse model of nonalcoholic steatohepatitis induced by high-fat high-carbohydrate diet[J]. Journal of Clinical Hepatology, 2024, 40(5): 952-960. doi: 10.12449/JCH240514
[3]	Shichun LU. Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1738-1740. doi: 10.12449/JCH240904
[4]	Chi MA, Guang TAN. Strategies and practice of conversion therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1725-1731. doi: 10.12449/JCH240902
[5]	Junzhe CAI, Songbai LIU, Xiaobin FEI, Peng LIU, Changhao ZHU, Xing WANG, Yaozhen PAN. Effect of ankyrin-repeat domain-containing protein 22 on human hepatoma cells and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(5): 989-996. doi: 10.12449/JCH240519
[6]	Kai CHANG, Yanyan WANG, Zhongyong JIANG, Wei SUN, Chenxia LIU, Wanlin NA, Hongxuan XU, Jing XIE, Yuan LIU, Min CHEN. Proteomic analysis and validation of DNA repair regulation in the process of hepatocellular carcinoma recurrence[J]. Journal of Clinical Hepatology, 2024, 40(2): 319-326. doi: 10.12449/JCH240216
[7]	Jiaqing LI, Xiaoyang XU, Zexin HU, Shen ZHANG, Binyan ZHONG, Xiaoli ZHU. Value of modified albumin-bilirubin grade in predicting the prognosis of patients with Child-Pugh class A unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs[J]. Journal of Clinical Hepatology, 2024, 40(12): 2450-2456. doi: 10.12449/JCH241215
[8]	Yanfang HE, Jiaojiao XIE, Lanlan ZHENG, Cai GUO, Yanhua MA. Expression and clinical significance of cell cycle protein-dependent kinase 1 and aurora kinase A in the serum of patients with hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(7): 1390-1396. doi: 10.12449/JCH240717
[9]	Jiannan QIU, Peng WANG, Yin CAO, Zhongxia WANG, Junhua WU, Chunping JIANG. Effect of kinesin family member 15 on the proliferation of hepatocellular carcinoma cells and its mechanism of action[J]. Journal of Clinical Hepatology, 2024, 40(2): 327-334. doi: 10.12449/JCH240217
[10]	Yijie ZHAO, Lu XIE, Yating ZHANG, Guangwei LIU. Pyroptosis： A new bridge connecting gut microbiota and liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(9): 1908-1915. doi: 10.12449/JCH240930
[11]	Quan ZHOU, Chunlin CAI, Jinqiang LI. Gut-liver axis： Intestinal microbial homeostasis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2710-2717. doi: 10.3969/j.issn.1001-5256.2023.11.029
[12]	Zhisong NI, Junhan WEN, Weiwei ZHAO, Shoujun YU, Liang HAO, Yu CHENG, Xin LIU. Neoadjuvant therapy for hepatocellular carcinoma： Current situation and prospects[J]. Journal of Clinical Hepatology, 2023, 39(11): 2697-2704. doi: 10.3969/j.issn.1001-5256.2023.11.027
[13]	Yuyan TANG, Shibin XIE, Jianyun ZHU. Diagnostic efficacy of alpha-fetoprotein and alpha-fetoprotein L3% in hepatitis B virus-related early-stage hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2607-2613. doi: 10.3969/j.issn.1001-5256.2023.11.014
[14]	Jingya YIN, Bingqing YANG, Yue LI. Role of pyroptosis in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(1): 175-180. doi: 10.3969/j.issn.1001-5256.2023.01.027
[15]	Yan YANG, Feilin GE, Qian HUANG, Xinyue ZHANG, Rui ZENG, Xiaohe XIAO, Zhaofang BAI, Qin SUN. Mechanism of action of nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome in liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(4): 942-946. doi: 10.3969/j.issn.1001-5256.2022.04.041
[16]	Minghao LIU, Sutong LIU, Dongfang SHANG, Lihui ZHANG, Yajiao GU, Wenxia ZHAO. Effect of Huatan Qushi Huoxue prescription on lipopolysaccharide-induced pyroptosis of macrophages[J]. Journal of Clinical Hepatology, 2022, 38(9): 2016-2019. doi: 10.3969/j.issn.1001-5256.2022.09.014
[17]	Xinyue WANG, Deguan LI. Mechanism of pyroptosis and its role in the development and progression of liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(12): 2976-2980. doi: 10.3969/j.issn.1001-5256.2021.12.051
[18]	Wei BiWei, Gong YaHui, Liang ZhiHai. Role of pyroptosis in the pathogenesis of acute pancreatitis[J]. Journal of Clinical Hepatology, 2020, 36(8): 1905-1908. doi: 10.3969/j.issn.1001-5256.2020.08.050
[19]	XIAO WeiSong, LE YingYu, ZENG ShengLan, TAN XiaoBin, WU Cong, YA ChengYu, MAO DeWen. Role of pyroptosis in liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2847-2850. doi: 10.3969/j.issn.1001-5256.2020.12.044
[20]	Fan Chang, Wu FuRong, Zhang JiaFu, Jiang Hui. Role of pyroptosis in the pathogenesis of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(5): 1138-1140. doi: 10.3969/j.issn.1001-5256.2020.05.042

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	周青青，潘陈为. MicroRNA-375低水平表达与乙肝肝细胞癌预后相关性分析. 中国药物滥用防治杂志. 2025(01): 46-50 .
2.	段淑文，魏亚君，武天凯，王晓辉，丁照然，刘灿，戴恩来. 基于NLRP3/Caspase-1/GSDMD通路对泼尼松联合淫羊藿苷提高激素抵抗型肾病综合征疗效的机制研究. 中国临床药理学与治疗学. 2024(10): 1081-1090 .
3.	沈赞，王冠尹，张镒，裴航，韦新士，王子月，陈志远，何帮剑. 激素性股骨头坏死中多重细胞死亡方式作用的研究进展. 中国骨质疏松杂志. 2024(12): 1832-1837 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3)

Get Citation

PDF

XML

Article Metrics

Article views (830) PDF downloads(57)